Showing results (181-190 of 223) with videos related to

Sort By:
Pageof 23
The Journal of Clinical Investigation|July 17, 2019
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damagePayel Chatterjee, Michael T Schweizer, Jared M Lucas, et al.
European Urology|July 7, 2020
A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide CohortsMark C Markowski, Hao Wang, Rana Sullivan, et al.
Biomaterials|March 29, 2016
A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancerOren Levy, W Nathaniel Brennen, Edward Han, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2020
Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapyLaura A Sena, Hao Wang, Su J Lim ScM, et al.
Oncogene|September 29, 2020
Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitorsYezi Zhu, Susan L Dalrymple, Ilsa Coleman, et al.
JCO Oncology Practice|February 19, 2026
Comparison of Characteristics and Outcomes of Patients With Metastatic Prostate Cancer With and Without Next-Generation Sequencing TestingMadelyn F Klugman, Hua-Ling Tsai, Yasaman Iranmanesh, et al.
The Prostate|May 28, 2015
A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determinationChanning J Paller, Michelle A Rudek, Xian C Zhou, et al.
Science Translational Medicine|June 30, 2012
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapySamuel R Denmeade, Annastasiah M Mhaka, D Marc Rosen, et al.
Molecular Cancer Therapeutics|September 18, 2020
Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate CancerOliver C Rogers, Lizamma Antony, Oren Levy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 18, 2010
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancerDaniel C Danila, Michael J Morris, Johann S de Bono, et al.
Pageof 23